We have two fantastic Canadian guest nephrologists discussing IgA nephropathy on this episode. Dr. Sean Barbour is an adult nephrologist and associate professor at the University of British Columbia. He is a glomerulonephritis and epidemiology expert and serves as the chair of the British Columbia GN Committee and Registry. He developed and validated the IgA clinical prediction tool for both adults and children and has participated in the TESTING and NefIgArd clinical trials. Dr. Alexandra Cambier is a clinician-scientist and an associate professor of pediatric nephrology at Montreal University. She also worked on the pediatric IgA prediction tool and has numerous publications regarding biomarkers and genetic variants in children with IgA nephropathy. 

Publications that we discuss in this episode-

IgA prediction tool validation:

https://pubmed.ncbi.nlm.nih.gov/30980653/ https://pubmed.ncbi.nlm.nih.gov/35490842/

https://pubmed.ncbi.nlm.nih.gov/33220356/

CD89 in childhood IgA nephropathy:

https://pubmed.ncbi.nlm.nih.gov/34756952/

IgA nephropathy therapies in children:

https://pubmed.ncbi.nlm.nih.gov/34756952/

Targeted-release budesonide in adults with IgA nephropathy:

https://pubmed.ncbi.nlm.nih.gov/36270561/